{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:06:07Z","timestamp":1791929167891,"version":"4.3.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,3]]},"DOI":"10.7759\/cureus.70768","type":"journal-article","created":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:42:09Z","timestamp":1727966529000},"source":"Crossref","is-referenced-by-count":10,"title":["Understanding Insulin Resistance in NAFLD: A Systematic Review and Meta-Analysis Focused on HOMA-IR in South Asians"],"prefix":"10.7759","author":[{"given":"Margeyi","family":"Mehta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigish","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urvish","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0365","article-title":"Global incidence and prevalence of nonalcoholic fatty liver disease","volume":"29","author":"Teng ML","year":"2023","unstructured":"Teng ML, Ng CH, Huang DQ, et al.. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S32-42. 10.3350\/cmh.2022.0365","journal-title":"Clin Mol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.21037\/tgh-23-118","article-title":"Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future","volume":"9","author":"Dong X","year":"2024","unstructured":"Dong X, Li JM, Lu XL, Lin XY, Hong MZ, Weng S, Pan JS. Global burden of adult non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) has been steadily increasing over the past decades and is expected to persist in the future. Transl Gastroenterol Hepatol. 2024, 9:33. 10.21037\/tgh-23-118","journal-title":"Transl Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s40200-023-01293-3","article-title":"Unraveling the link between insulin resistance and non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): a narrative review","volume":"22","author":"Ziamanesh F","year":"2023","unstructured":"Ziamanesh F, Mohammadi M, Ebrahimpour S, Tabatabaei-Malazy O, Mosallanejad A, Larijani B. Unraveling the link between insulin resistance and non-alcoholic fatty liver disease (or metabolic dysfunction-associated steatotic liver disease): a narrative review. J Diabetes Metab Disord. 2023, 22:1083-94. 10.1007\/s40200-023-01293-3","journal-title":"J Diabetes Metab Disord"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(22)00317-X","article-title":"Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis","volume":"8","author":"Quek J","year":"2023","unstructured":"Quek J, Chan KE, Wong ZY, et al.. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023, 8:20-30. 10.1016\/S2468-1253(22)00317-X","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1186\/1743-7075-7-26","article-title":"Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007)","volume":"7","author":"Esteghamati A","year":"2010","unstructured":"Esteghamati A, Ashraf H, Khalilzadeh O, et al.. Optimal cut-off of homeostasis model assessment of insulin resistance (HOMA-IR) for the diagnosis of metabolic syndrome: third national surveillance of risk factors of non-communicable diseases in Iran (SuRFNCD-2007). Nutr Metab (Lond). 2010, 7:26. 10.1186\/1743-7075-7-26","journal-title":"Nutr Metab (Lond)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqy092.162","article-title":"Specific cutoffs for HOMA1-IR, HOMA2-IR, HOMA1-%B, and HOMA2-%B in adult Egyptian patients","volume":"21","author":"Elsafty A","year":"2018","unstructured":"Elsafty A, Nabhan S, Mahmoud MSH, et al.. Specific cutoffs for HOMA1-IR, HOMA2-IR, HOMA1-%B, and HOMA2-%B in adult Egyptian patients. Am J Clin Pathol. 2018, 21:66. 10.1093\/ajcp\/aqy092.162","journal-title":"Am J Clin Pathol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.atv.16.2.281","article-title":"Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures","volume":"16","author":"Mitchell BD","year":"1996","unstructured":"Mitchell BD, Kammerer CM, Mahaney MC, et al.. Genetic analysis of the IRS. Pleiotropic effects of genes influencing insulin levels on lipoprotein and obesity measures. Arterioscler Thromb Vasc Biol. 1996, 16:281-8. 10.1161\/01.atv.16.2.281","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1590\/s0004-27302009000200020","article-title":"HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS)","volume":"53","author":"Geloneze B","year":"2009","unstructured":"Geloneze B, Vasques AC, Stabe CF, Pareja JC, Rosado LE, Queiroz EC, Tambascia MA. HOMA1-IR and HOMA2-IR indexes in identifying insulin resistance and metabolic syndrome: Brazilian Metabolic Syndrome Study (BRAMS). Arq Bras Endocrinol Metabol. 2009, 53:281-7. 10.1590\/s0004-27302009000200020","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2013.09.018","article-title":"Obesity-associated nonalcoholic fatty liver disease","volume":"18","author":"Yilmaz Y","year":"2014","unstructured":"Yilmaz Y, Younossi ZM. Obesity-associated nonalcoholic fatty liver disease. Clin Liver Dis. 2014, 18:19-31. 10.1016\/j.cld.2013.09.018","journal-title":"Clin Liver Dis"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease","volume":"62","author":"Byrne CD","year":"2015","unstructured":"Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol. 2015, 62:S47-64. 10.1016\/j.jhep.2014.12.012","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.01.032","article-title":"The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent","volume":"150","author":"Mancina RM","year":"2016","unstructured":"Mancina RM, Dongiovanni P, Petta S, et al.. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology. 2016, 150:1219-1230.e6. 10.1053\/j.gastro.2016.01.032","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews DR","year":"1985","unstructured":"Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985, 28:412-9. 10.1007\/BF00280883","journal-title":"Diabetologia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000111245.75752.C6","article-title":"Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition","volume":"109","author":"Grundy SM","year":"2004","unstructured":"Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute\/American Heart Association conference on scientific issues related to definition. Circulation. 2004, 109:433-8. 10.1161\/01.CIR.0000111245.75752.C6","journal-title":"Circulation"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.6.1487","article-title":"Use and abuse of HOMA modeling","volume":"27","author":"Wallace TM","year":"2004","unstructured":"Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004, 27:1487-95. 10.2337\/diacare.27.6.1487","journal-title":"Diabetes Care"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.50.8.1844","article-title":"Nonalcoholic fatty liver disease: a feature of the metabolic syndrome","volume":"50","author":"Marchesini G","year":"2001","unstructured":"Marchesini G, Brizi M, Bianchi G, et al.. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001, 50:1844-50. 10.2337\/diabetes.50.8.1844","journal-title":"Diabetes"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.84.1.5393","article-title":"Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women","volume":"84","author":"Legro RS","year":"1999","unstructured":"Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999, 84:165-9. 10.1210\/jcem.84.1.5393","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2011.06.002","article-title":"Insulin resistance: the link between obesity and cardiovascular disease","volume":"95","author":"Reaven GM","year":"2011","unstructured":"Reaven GM. Insulin resistance: the link between obesity and cardiovascular disease. Med Clin North Am. 2011, 95:875-92. 10.1016\/j.mcna.2011.06.002","journal-title":"Med Clin North Am"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.146874","article-title":"Assessment of insulin sensitivity\/resistance","volume":"19","author":"Gutch M","year":"2015","unstructured":"Gutch M, Kumar S, Razi SM, Gupta KK, Gupta A. Assessment of insulin sensitivity\/resistance. Indian J Endocrinol Metab. 2015, 19:160-4. 10.4103\/2230-8210.146874","journal-title":"Indian J Endocrinol Metab"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1172\/JCI24531","article-title":"Gestational diabetes mellitus","volume":"115","author":"Buchanan TA","year":"2005","unstructured":"Buchanan TA, Xiang AH. Gestational diabetes mellitus. J Clin Invest. 2005, 115:485-91. 10.1172\/JCI24531","journal-title":"J Clin Invest"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2012.04.001","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology","volume":"142","author":"Chalasani N","year":"2012","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology. 2012, 142:1592-609. 10.1053\/j.gastro.2012.04.001","journal-title":"Gastroenterology"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v16.i42.5286","article-title":"Histopathology of nonalcoholic fatty liver disease","volume":"16","author":"Brunt EM","year":"2010","unstructured":"Brunt EM, Tiniakos DG. Histopathology of nonalcoholic fatty liver disease. World J Gastroenterol. 2010, 16:5286-96. 10.3748\/wjg.v16.i42.5286","journal-title":"World J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner DE","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, et al.. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005, 41:1313-21. 10.1002\/hep.20701","journal-title":"Hepatology"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo P","year":"2002","unstructured":"Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002, 346:1221-31. 10.1056\/NEJMra011775","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","year":"2016","unstructured":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016, 64.1388-402. 10.1016\/j.jhep.2015.11.004","journal-title":"J Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al.. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021, 372:n160. 10.1136\/bmj.n160","journal-title":"BMJ"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-006-9136-y","article-title":"The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West","volume":"52","author":"Duseja A","year":"2007","unstructured":"Duseja A, Das A, Das R, Dhiman RK, Chawla Y, Bhansali A, Kalra N. The clinicopathological profile of Indian patients with nonalcoholic fatty liver disease (NAFLD) is different from that in the West. Dig Dis Sci. 2007, 52:2368-74. 10.1007\/s10620-006-9136-y","journal-title":"Dig Dis Sci"},{"key":"ref29","article-title":"A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease","volume":"129","author":"Bajaj S","year":"2009","unstructured":"Bajaj S, Nigam P, Luthra A, et al.. A case-control study on insulin resistance, metabolic co-variates & prediction score in non-alcoholic fatty liver disease. Indian J Med Res. 2009, 129:285-92.","journal-title":"Indian J Med Res"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.06.016","article-title":"Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy","volume":"203","author":"Sharma R","year":"2009","unstructured":"Sharma R, Sinha S, Danishad KA, et al.. Investigation of hepatic gluconeogenesis pathway in non-diabetic Asian Indians with non-alcoholic fatty liver disease using in vivo ((31)P) phosphorus magnetic resonance spectroscopy. Atherosclerosis. 2009, 203:291-7. 10.1016\/j.atherosclerosis.2008.06.016","journal-title":"Atherosclerosis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2012.02.015","article-title":"Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population","volume":"5","author":"Sanal MG","year":"2011","unstructured":"Sanal MG, Sarin SK. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr. 2011, 5:76-80. 10.1016\/j.dsx.2012.02.015","journal-title":"Diabetes Metab Syndr"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2012.09.067","article-title":"Association of peroxisome proliferator activated receptor-\u03b3 gene with non-alcoholic fatty liver disease in Asian Indians residing in north India","volume":"512","author":"Bhatt SP","year":"2013","unstructured":"Bhatt SP, Nigam P, Misra A, Guleria R, Luthra K, Pandey RM, Pasha MA. Association of peroxisome proliferator activated receptor-\u03b3 gene with non-alcoholic fatty liver disease in Asian Indians residing in north India. Gene. 2013, 512:143-7. 10.1016\/j.gene.2012.09.067","journal-title":"Gene"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0213","article-title":"Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians","volume":"14","author":"Kuppan G","year":"2012","unstructured":"Kuppan G, Anjana RM, Deepa M, Paramasivam P, Chandrakumar S, Kaliyaperumal V, Mohan V. Inflammatory markers in relation to nonalcoholic fatty liver disease in urban South Indians. Diabetes Technol Ther. 2012, 14:152-8. 10.1089\/dia.2011.0213","journal-title":"Diabetes Technol Ther"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2015.09.001","article-title":"Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study","volume":"5","author":"Singh SP","year":"2015","unstructured":"Singh SP, Singh A, Misra D, et al.. Risk factors associated with non-alcoholic fatty liver disease in Indians: a case-control study. J Clin Exp Hepatol. 2015, 5:295-302. 10.1016\/j.jceh.2015.09.001","journal-title":"J Clin Exp Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1007\/s12291-016-0612-7","article-title":"Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation","volume":"32","author":"Swain M","year":"2017","unstructured":"Swain M, Nath P, Parida PK, et al.. Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation. Indian J Clin Biochem. 2017, 32:306-14. 10.1007\/s12291-016-0612-7","journal-title":"Indian J Clin Biochem"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.02.011","article-title":"rs7903146 (C\/T) polymorphism of transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians","volume":"14","author":"Bhatt SP","year":"2020","unstructured":"Bhatt SP, Misra A, Pandey RM. rs7903146 (C\/T) polymorphism of transcription factor 7 like 2 (TCF7L-2) gene is independently associated with non-alcoholic fatty liver disease in Asian Indians. Diabetes Metab Syndr. 2020, 14:175-80. 10.1016\/j.dsx.2020.02.011","journal-title":"Diabetes Metab Syndr"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2021.102261","article-title":"Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India","volume":"15","author":"Kamalraj N","year":"2021","unstructured":"Kamalraj N, Sathishkumar M, Arunvignesh M, et al.. Retrospective analysis (2009-2017) of factors associated with progression and regression of non-alcoholic fatty liver disease (hepatic steatosis) in patients with type 2 diabetes seen at a tertiary diabetes centre in Southern India. Diabetes Metab Syndr. 2021, 15:102261. 10.1016\/j.dsx.2021.102261","journal-title":"Diabetes Metab Syndr"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s13410-022-01058-3","article-title":"Lipocalin-2 levels increase in plasma of non-alcoholic fatty liver disease patients with metabolic syndrome","volume":"43","author":"Chawla H","year":"2022","unstructured":"Chawla H, Bhosale V, Misra R, et al.. Lipocalin-2 levels increase in plasma of non-alcoholic fatty liver disease patients with metabolic syndrome. Int J Diabetes Dev Ctries. 2022, 43:105-12. 10.1007\/s13410-022-01058-3","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.47009\/jamp.2022.4.5.5","article-title":"Relation of insulin resistance in non-alcoholic fatty liver disease","volume":"4","author":"Mishra A","year":"2022","unstructured":"Mishra A, Sahoo RL, Sundar PS. Relation of insulin resistance in non-alcoholic fatty liver disease. Int J Acad Med Pharm. 2022, 4:17-22. 10.47009\/jamp.2022.4.5.5","journal-title":"Int J Acad Med Pharm"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2023.2279676","article-title":"The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis","volume":"40","author":"Shinde S","year":"2024","unstructured":"Shinde S, Nelson DR, Mitroi J, Heaton PC, Hincapie AL, Brouwers B. The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease\/non-alcoholic steatohepatitis. Curr Med Res Opin. 2024, 40:59-68. 10.1080\/03007995.2023.2279676","journal-title":"Curr Med Res Opin"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59788","article-title":"Linking non-alcoholic fatty liver disease severity with metabolic syndrome features: an integrative study on clinical and radiological fronts","volume":"16","author":"Sukumar M","year":"2024","unstructured":"Sukumar M, Vikram NK, Ranjan P, et al.. Linking non-alcoholic fatty liver disease severity with metabolic syndrome features: an integrative study on clinical and radiological fronts. Cureus. 2024, 16:e59788. 10.7759\/cureus.59788","journal-title":"Cureus"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i21.3400","article-title":"Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians","volume":"12","author":"Madan K","year":"2006","unstructured":"Madan K, Batra Y, Gupta SD, et al.. Non-alcoholic fatty liver disease may not be a severe disease at presentation among Asian Indians. World J Gastroenterol. 2006, 12:3400-5. 10.3748\/wjg.v12.i21.3400","journal-title":"World J Gastroenterol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S1665-2681(19)31806-X","article-title":"Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD)","volume":"8","author":"Kalra N","year":"2009","unstructured":"Kalra N, Duseja A, Das A, et al.. Chemical shift magnetic resonance imaging is helpful in detecting hepatic steatosis but not fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Ann Hepatol. 2009, 8:21-5. 10.1016\/S1665-2681(19)31806-X","journal-title":"Ann Hepatol"},{"key":"ref44","article-title":"Comparison of non-invasive scoring systems with ultrasound and liver elastography in predicting non-alcoholic fatty liver disease in healthy population","volume":"22","author":"Balankhe K","year":"2021","unstructured":"Balankhe K, Nayak RR, Modi RK, et al.. Comparison of non-invasive scoring systems with ultrasound and liver elastography in predicting non-alcoholic fatty liver disease in healthy population. J Indian Acad Clin Med. 2021, 22:99-103.","journal-title":"J Indian Acad Clin Med"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2021\/51585.15600","article-title":"Metabolic profile of lean\/non obese NAFLD (non alcoholic fatty liver disease) subjects","volume":"15","author":"Jaiswal A","year":"2021","unstructured":"Jaiswal A, Jain K, Babu N. Metabolic profile of lean\/non obese NAFLD (non alcoholic fatty liver disease) subjects. J Clin Diag Res. 2021, 15:OC01-OC05. 10.7860\/JCDR\/2021\/51585.15600","journal-title":"J Clin Diag Res"},{"key":"ref46","article-title":"Factors influencing online prediction tools of non-alcoholic fatty liver disease","volume":"12","author":"Ravali RS","year":"2021","unstructured":"Ravali RS, Lakshmi KS, Vijayakumar TM, Kumar JS. Factors influencing online prediction tools of non-alcoholic fatty liver disease. J Cardiovasc Dis Res. 2021, 12:248-56.","journal-title":"J Cardiovasc Dis Res"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.7869\/tg.2012.86","article-title":"Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease","volume":"34","author":"Bhat G","year":"2013","unstructured":"Bhat G, Baba CS, Pandey A, Kumari N, Choudhuri G. Insulin resistance and metabolic syndrome in nonobese Indian patients with non-alcoholic fatty liver disease. Trop Gastroenterol. 2013, 34:18-24. 10.7869\/tg.2012.86","journal-title":"Trop Gastroenterol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1038\/s41430-022-01111-8","article-title":"Effect of intensive weight-loss intervention on metabolic, ultrasound and anthropometric parameters among patients with obesity and non-alcoholic fatty liver disease: an RCT","volume":"76","author":"Arora C","year":"2022","unstructured":"Arora C, Malhotra A, Ranjan P, et al.. Effect of intensive weight-loss intervention on metabolic, ultrasound and anthropometric parameters among patients with obesity and non-alcoholic fatty liver disease: an RCT. Eur J Clin Nutr. 2022, 76:1332-8. 10.1038\/s41430-022-01111-8","journal-title":"Eur J Clin Nutr"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2023.08.016","article-title":"Digital twin-enabled personalized nutrition improves metabolic dysfunction-associated fatty liver disease in type 2 diabetes: results of a 1-year randomized controlled study","volume":"29","author":"Joshi S","year":"2023","unstructured":"Joshi S, Shamanna P, Dharmalingam M, Vadavi A, Keshavamurthy A, Shah L, Mechanick JI. Digital twin-enabled personalized nutrition improves metabolic dysfunction-associated fatty liver disease in type 2 diabetes: results of a 1-year randomized controlled study. Endocr Pract. 2023, 29:960-70. 10.1016\/j.eprac.2023.08.016","journal-title":"Endocr Pract"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem H","year":"2011","unstructured":"Balshem H, Helfand M, Sch\u00fcnemann HJ, et al.. GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011, 64:401-6. 10.1016\/j.jclinepi.2010.07.015","journal-title":"J Clin Epidemiol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70032-4","article-title":"Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome","volume":"2","author":"Yki-J\u00e4rvinen H","year":"2014","unstructured":"Yki-J\u00e4rvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014, 2:901-10. 10.1016\/S2213-8587(14)70032-4","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2008.10.010","article-title":"Epidemiology of non-alcoholic fatty liver disease in China","volume":"50","author":"Fan JG","year":"2009","unstructured":"Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009, 50:204-10. 10.1016\/j.jhep.2008.10.010","journal-title":"J Hepatol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni G","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006, 6:33. 10.1186\/1471-230X-6-33","journal-title":"BMC Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-023597","article-title":"Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study","volume":"9","author":"Vilar-Gomez E","year":"2019","unstructured":"Vilar-Gomez E, Athinarayanan SJ, Adams RN, et al.. Post hoc analyses of surrogate markers of non-alcoholic fatty liver disease (NAFLD) and liver fibrosis in patients with type 2 diabetes in a digitally supported continuous care intervention: an open-label, non-randomised controlled study. BMJ Open. 2019, 9:e023597. 10.1136\/bmjopen-2018-023597","journal-title":"BMJ Open"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0249","article-title":"Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: potential benefits and limitations","volume":"28","author":"Kim SS","year":"2022","unstructured":"Kim SS, Cheong JY. Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: potential benefits and limitations. Clin Mol Hepatol. 2022, 28:802-5. 10.3350\/cmh.2022.0249","journal-title":"Clin Mol Hepatol"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1186\/s12944-017-0409-6","article-title":"The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease","volume":"16","author":"Zhang S","year":"2017","unstructured":"Zhang S, Du T, Zhang J, et al.. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017, 16:15. 10.1186\/s12944-017-0409-6","journal-title":"Lipids Health Dis"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000055014.62083.05","article-title":"C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women","volume":"107","author":"Ridker PM","year":"2003","unstructured":"Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003, 107:391-7. 10.1161\/01.cir.0000055014.62083.05","journal-title":"Circulation"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0350","article-title":"Comparison between obese and non-obese nonalcoholic fatty liver disease","volume":"29","author":"Chan WK","year":"2023","unstructured":"Chan WK. Comparison between obese and non-obese nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023, 29:S58-67. 10.3350\/cmh.2022.0350","journal-title":"Clin Mol Hepatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/299527-understanding-insulin-resistance-in-nafld-a-systematic-review-and-meta-analysis-focused-on-homa-ir-in-south-asians","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,3]],"date-time":"2024-10-03T14:42:12Z","timestamp":1727966532000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/299527-understanding-insulin-resistance-in-nafld-a-systematic-review-and-meta-analysis-focused-on-homa-ir-in-south-asians"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,3]]},"references-count":58,"URL":"https:\/\/doi.org\/10.7759\/cureus.70768","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,3]]}}}